blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3071205

EP3071205 - BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.12.2020
Database last updated on 04.12.2024
FormerThe patent has been granted
Status updated on  03.01.2020
FormerGrant of patent is intended
Status updated on  07.08.2019
FormerExamination is in progress
Status updated on  23.03.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Forma Therapeutics, Inc.
500 Arsenal St., Suite 100
Watertown, MA 02472 / US
[2016/39]
Inventor(s)01 / BAIR, Kenneth, W.
41 Cartwright Road
Wellesley, Massachusetts 02482 / US
02 / HERBERTZ, Torsten
25 Woodland Way
Stow, Massachusetts 01775 / US
03 / KAUFFMAN, Goss, Stryker
4 Cranwood Road
Ledyard, Connecticut 06339 / US
04 / KAYSER-BRICKER, Katherine, J.
186 Alps Road
Branford, Connecticut 06405 / US
05 / LUKE, George, P.
17 Vienna Lane
Clinton, Connecticut 06413 / US
06 / MARTIN, Matthew, W.
98 Forest Street
Arlington, Massachusetts 02474 / US
07 / MILLAN, David, S.
c/o Forma Therapeutics, Inc.
500 Arsenal Street, Suite 100
Watertown, Massachusetts 02472 / US
08 / SCHILLER, Shawn, E. R.
614 Hilldale Avenue
Haverhill, Massachusetts 01832 / US
09 / TALBOT, Adam, C.
3 Hart Landing
Guilford, Connecticut 06437 / US
10 / TEBBE, Mark, J.
282 Renfrew Street
Arlington, Massachusetts 02476 / US
 [2016/39]
Representative(s)Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
[N/P]
Former [2020/06]Grund, Martin
Grund Intellectual Property Group
Patentanwalt und Solicitor PartG mbB
Postfach 44 05 16
80754 München / DE
Former [2016/39]Grund, Martin
Grund
Intellectual Property Group
Postfach 44 05 16
80754 München / DE
Application number, filing date14862659.118.11.2014
[2016/39]
WO2014US66235
Priority number, dateUS201361905633P18.11.2013         Original published format: US 201361905633 P
US201462054806P24.09.2014         Original published format: US 201462054806 P
[2016/39]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015074081
Date:21.05.2015
Language:EN
[2015/20]
Type: A1 Application with search report 
No.:EP3071205
Date:28.09.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 21.05.2015 takes the place of the publication of the European patent application.
[2016/39]
Type: B1 Patent specification 
No.:EP3071205
Date:05.02.2020
Language:EN
[2020/06]
Search report(s)International search report - published on:US21.05.2015
(Supplementary) European search report - dispatched on:EP12.04.2017
ClassificationIPC:A61K31/53, A61K31/4985, C07D487/04
[2016/39]
CPC:
C07D498/04 (EP,US); A61K31/498 (EP,US); A61K31/4985 (EP,RU,US);
A61K31/5025 (EP,US); A61K31/506 (EP,US); A61K31/517 (EP,US);
A61K31/519 (EP,US); A61K31/53 (EP,RU,US); A61K31/5377 (EP,US);
A61K31/541 (EP,US); A61K31/55 (EP,US); A61K31/551 (EP,US);
A61K31/553 (EP,US); A61K45/06 (EP,US); A61P15/16 (RU);
A61P19/02 (RU); A61P3/04 (RU); A61P35/00 (RU);
C07D241/42 (EP,RU,US); C07D241/50 (EP,US); C07D401/04 (EP,US);
C07D401/06 (EP,US); C07D401/10 (EP,US); C07D401/12 (EP,US);
C07D401/14 (EP,US); C07D403/04 (EP,US); C07D403/06 (EP,US);
C07D403/10 (EP,US); C07D403/12 (EP,US); C07D403/14 (EP,US);
C07D405/04 (EP,US); C07D405/06 (EP,US); C07D405/10 (EP,US);
C07D405/12 (EP,US); C07D405/14 (EP,US); C07D409/06 (EP,US);
C07D409/12 (EP,US); C07D409/14 (EP,US); C07D413/04 (EP,US);
C07D413/06 (EP,US); C07D413/12 (EP,US); C07D413/14 (EP,US);
C07D417/04 (EP,US); C07D417/06 (EP,US); C07D417/10 (EP,US);
C07D417/14 (EP,US); C07D451/04 (EP,US); C07D471/04 (EP,US);
C07D487/04 (EP,US); C07D487/08 (EP,US); C07D491/048 (EP,US);
C07D495/04 (EP,US) (-)
C-Set:
A61K31/4985, A61K2300/00 (EP,US);
A61K31/498, A61K2300/00 (US,EP);
A61K31/5025, A61K2300/00 (US,EP);
A61K31/519, A61K2300/00 (EP,US);
A61K31/53, A61K2300/00 (US,EP)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/39]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:BENZOPIPERAZINZUSAMMENSETZUNGEN ALS BET-BROMDOMÄNENHEMMER[2016/39]
English:BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS[2016/39]
French:COMPOSITIONS DE BENZOPIPÉRAZINE EN TANT QU'INHIBITEURS DE BROMODOMAINES BET[2016/39]
Entry into regional phase17.06.2016National basic fee paid 
17.06.2016Search fee paid 
17.06.2016Designation fee(s) paid 
17.06.2016Examination fee paid 
Examination procedure17.06.2016Examination requested  [2016/39]
10.11.2017Amendment by applicant (claims and/or description)
22.03.2018Despatch of a communication from the examining division (Time limit: M06)
10.09.2018Reply to a communication from the examining division
24.09.2018Despatch of a communication from the examining division (Time limit: M04)
07.12.2018Reply to a communication from the examining division
08.08.2019Communication of intention to grant the patent
17.12.2019Fee for grant paid
17.12.2019Fee for publishing/printing paid
17.12.2019Receipt of the translation of the claim(s)
Opposition(s)06.11.2020No opposition filed within time limit [2021/02]
Fees paidRenewal fee
28.11.2016Renewal fee patent year 03
08.11.2017Renewal fee patent year 04
08.11.2018Renewal fee patent year 05
14.11.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU18.11.2014
AL05.02.2020
AT05.02.2020
CY05.02.2020
CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
IT05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
MK05.02.2020
MT05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
TR05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
[2022/31]
Former [2022/30]HU18.11.2014
AL05.02.2020
AT05.02.2020
CY05.02.2020
CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
IT05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
MT05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
TR05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2022/27]HU18.11.2014
AT05.02.2020
CY05.02.2020
CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
IT05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
MT05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
TR05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2021/31]AT05.02.2020
CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
IT05.02.2020
LT05.02.2020
LV05.02.2020
MC05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2021/10]AT05.02.2020
CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
IT05.02.2020
LT05.02.2020
LV05.02.2020
PL05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SI05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/50]CZ05.02.2020
DK05.02.2020
EE05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/49]CZ05.02.2020
DK05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SK05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/48]DK05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
RO05.02.2020
RS05.02.2020
SE05.02.2020
SM05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/47]DK05.02.2020
ES05.02.2020
FI05.02.2020
HR05.02.2020
LT05.02.2020
LV05.02.2020
RS05.02.2020
SE05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/40]FI05.02.2020
HR05.02.2020
LV05.02.2020
RS05.02.2020
SE05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
IS05.06.2020
PT28.06.2020
Former [2020/39]FI05.02.2020
HR05.02.2020
LV05.02.2020
RS05.02.2020
SE05.02.2020
BG05.05.2020
NO05.05.2020
GR06.05.2020
PT28.06.2020
Former [2020/38]FI05.02.2020
HR05.02.2020
LV05.02.2020
RS05.02.2020
SE05.02.2020
NO05.05.2020
GR06.05.2020
PT28.06.2020
Former [2020/37]FI05.02.2020
HR05.02.2020
LV05.02.2020
RS05.02.2020
SE05.02.2020
NO05.05.2020
PT28.06.2020
Former [2020/36]FI05.02.2020
RS05.02.2020
NO05.05.2020
PT28.06.2020
Former [2020/35]FI05.02.2020
NO05.05.2020
Documents cited:Search[X]WO2004085401  (PFIZER PROD INC [US], et al) [X] 1-15 * page 80 - page 81; examples 170-409; claims 1, 5, 10 *;
 [A]WO2011054848  (GLAXOSMITHKLINE LLC [US], et al) [A] 1-15* claims 1, 25, 32 *
International search[A]US7101869  (BLUMENKOPF TODD A [US], et al);
 [A]US2010179325  (SUZUKI RYO [JP], et al);
 [A]US2010267672  (JUNG KYUNG-YUN [KR], et al)
by applicantUS5262564
 WO2004085401
 WO2011054848
    - MULLER, S.; FILIPPAKOPOULOS, P.; KNAPP, S., "Bromodomains as therapeutic targets", Expert Rev. Mol. Med., (20110000), vol. 13, doi:doi:10.1017/s1462399411001992, page e29, XP002670944

DOI:   http://dx.doi.org/10.1017/s1462399411001992
    - NICODEME et al., Nature, (20100000), vol. 468, page 1119
    - DHALLUIN C.; CARLSON J.E.; ZENG L.; HE C.; AGGARWAL A.K.; ZHOU M.M., "Structure and ligand of a histone acetyltransferase bromodomain", Nature, (19990000), vol. 399, pages 491 - 6
    - CRAWFORD, N.P; ALSARRAJ, J.; LUKES, L.; WALKER, R.C.; OFFICEWALA, J.S.; YANG, H.H.; LEE, M.P.; OZATO, K.; HUNTER, K.W., "Bromodomain 4 Activation Predicts Breast Cancer Survival", Proc. Natl. Acad. Sci. USA., (20080000), vol. 105, no. 17, pages 6380 - 6385
    - GUO, N.; FALLER, D.V.; DENIS, G.V., "Activation-Induced Nuclear Translocation of RING3", J. Cell Sci., (20010000), vol. 113, no. 17, pages 3085 - 3091
    - DELMORE J.E.; ISSA G.C.; LEMIEUX M.E.; RAHL, P.B.; SHI J.; JACOBS H.M., "BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc", Cell, (20110000), vol. 146, doi:doi:10.1016/j.cell.2011.08.017, pages 904 - 17, XP028295705

DOI:   http://dx.doi.org/10.1016/j.cell.2011.08.017
    - DAWSON, M. A; PRINJHA, R.K.; DITTMAN, A.; GIOTOPOULOS, G.; BANTCHEFF, M.; CHAN, W-I.; ROBSON, S.C.; CHUNG, C.; HOPF, C.; SAVITSKI,, "Inhibition of BET recruitment of chromatin as an effective treatment of MLL-fusion leukemia", Nature, (20110000), vol. 0, pages 1 - 5
    - PICAUD, S.; DA COSTA, D.; THANASOPOULOU, A.; FILIPPAKOPOULOS, P.; FISH, P.; PHILPOTT, M.; FEDEROV, O.; BRENNAN, P.; BUNNAGE, M. E., "PFI-1 - A highly Selective Protein Interaction Inhibitor Targeting BET Bromodomains", Cancer Res., (20130000), vol. 73, no. 11, doi:doi:10.1158/0008-5472.CAN-12-3292, pages 3336 - 3346, XP055130754

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-12-3292
    - S. BERGE et al., Journal of Pharmaceutical Sciences, (19770000), vol. 66, no. 1, pages 1 - 19
    - P. GOULD, International J. of Pharmaceutics, (19860000), vol. 33, pages 201 - 217
    - The Orange Book, Food & Drug Administration
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.